Cymabay Therapeu (CBAY) Peer Comparison

$32.48

$0.00 (0.00%)

As on 25-Mar-2024 09:30EDT

Market cap

$3,728 Mln

Revenue (TTM)

$31 Mln

P/E Ratio

--

P/B Ratio

12.8

Div. Yield

0 %

Edit

	Cymabay Therapeu (CBAY)	AgeX Therapeutics (AGE)
Market cap ($ Mln)	3,728	28
Revenue ($ Mln)	31	0
Net Profit ($ Mln)	-105.37	-14.80
Net Margin (%)	-332.64	-14,191.67
RoE (%)	-64.17	252.12
Price to Earnings	--	--
Price-To-Book	12.76	5.08

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Cymabay Therapeu (CBAY)	AgeX Therapeutics (AGE)
Operating Revenue	31.07	0.14
Cost of Revenue	0.68	0.17
Gross Profit	30.39	-0.03
Operating Expenses	132.07	9.93
Operating Profit (EBIT)	-101.68	-9.96
Other Income	--	--
Profit before Tax	-105.37	-14.81
Provision for Tax	--	-0.01
Profit after Tax (Net Income)	-105.37	-14.80
Minority Interest	--	--
Consolidated Profit	--	--

Liabilities ($ Mln)

	Cymabay Therapeu (CBAY)	AgeX Therapeutics (AGE)
Shareholder's Funds	292.26	5.47
Minority Interest	--	--
Non-Current Liabilities	105.59	0.69
Current Liabilities	36.84	5.91
Total Liabilities	434.69	11.97

Assets ($ Mln)

	Cymabay Therapeu (CBAY)	AgeX Therapeutics (AGE)
Non-Current Assets	30.88	11.21
Current Assets	403.80	0.75
Total Assets	434.69	11.97
Total Debt*	114.49	4.37
Net Current Assets	366.96	-5.16

Cashflow ($ Mln)

	Cymabay Therapeu (CBAY)	AgeX Therapeutics (AGE)
Cash From Operating Activities	-72.53	-7.80
Cash Flow from Investing Activities	--	--
Cash from Financing Activities	345.77	17.50
Net Cash Inflow / Outflow	--	--

Ratios

Profitability Ratios

	Cymabay Therapeu (CBAY)	AgeX Therapeutics (AGE)
ROCE (%)	-39.48	-275.51
ROE (%)	-64.17	252.12
ROA (%)	-36.55	-194.70
EBIT Margin (%)	--	--
Net Margin (%)	-339.10	-10,424.65
Cash Profit Margin (%)	--	--

Growth Ratios

	Cymabay Therapeu (CBAY)	AgeX Therapeutics (AGE)
Revenue Growth (%)	0.00	3.18
EBIT Growth (%)	--	--
Net Profit Growth (%)	11.37	-38.68
EPS Growth (%)	0.26	-0.39
Book Value Growth (%)	--	--

Valuation Ratios

	Cymabay Therapeu (CBAY)	AgeX Therapeutics (AGE)
Price / Earnings	-23.76	-0.03
Price / Book Value	8.57	0.08
Dividend Yield (%)	--	--
EV/EBITDA	-22.02	-0.45
Market Cap ($ Cr)	--	--

Solvency Ratios

	Cymabay Therapeu (CBAY)	AgeX Therapeutics (AGE)
Debt to Equity	0.39	0.80
Short term debt to equity ratio	0.03	0.67
Current Ratio	10.96	0.13
Quick Ratio	--	--
Interest Coverage	-5.37	-2.03

Operating Efficiency Ratios

	Cymabay Therapeu (CBAY)	AgeX Therapeutics (AGE)
Debtors to sales (%)	--	40.14
Asset Turnover	0.11	0.02
Receivable days	34.19	78.45
Inventory Days	--	--
Payable days	1,320.48	2,613.35
Cash Conversion Cycle	--	--

Annual
Quarterly